13F Holdings
中文EN

CVSI CV Sciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1510964 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-12.9%
TTM net income YoY-16.2%
TTM EPS YoY—
Revenue 3-yr CAGR-8.0%
Net income 3-yr CAGR—

Margins

Gross margin49.5%
Operating margin-2.5%
Net margin-13.7%
FCF margin-1.5%
EBITDA margin-1.8%

Returns

ROE-90.1%
ROA-25.6%
ROIC (approx.)-12.3%
Asset turnover1.86x

Leverage & solvency

Liabilities / assets64.7%
Debt / equity0.00x
Current ratio1.18x
Interest coverage-1.42x

Cash quality & payout

Operating cash flow / net income0.10x
Accruals ratio-23.0%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$13.79M$15.71M$16.00M$16.20M$20.05M
Cost of revenue$7.04M$8.54M$8.92M$10.65M$11.43M
Gross profit$6.75M$7.17M$7.08M$5.55M$8.62M
R&D expense$122,000$118,000$151,000$307,000$1.19M
SG&A expense$7.62M$9.24M$9.74M$12.09M$25.88M
Operating income-$470,000-$2.19M$3.36M-$6.85M-$18.45M
Interest expense$517,000$212,000—$600,000$38,000
Pretax income-$949,000-$2.40M$3.10M-$8.26M-$15.64M
Income tax$9,000-$8,000-$6,000-$47,000-$87,000
Net income-$958,000-$2.39M$3.10M-$8.21M-$15.55M
EBITDA-$278,000-$1.86M$3.60M-$5.86M-$17.29M
EPS (basic)-0.01-0.010.02-0.07-0.14
EPS (diluted)-0.01-0.010.02-0.07-0.14
Weighted avg. shares (diluted)184.26M175.59M153.96M138.03M107.82M
Banking
Net interest income———-$1.54M-$140,000
Balance sheet
Cash & equivalents$278,000$454,000$1.32M$611,000$1.38M
Receivables$402,000$522,000$431,000$766,000$2.04M
Inventory$4.09M$4.90M$5.66M$6.56M$8.62M
Current assets$5.13M$6.24M$7.94M$11.13M$14.19M
PP&E, net$344,000$399,000$379,000$575,000$1.72M
Goodwill$1.01M$971,000$342,000$0$0
Intangibles$76,000$93,000$78,000$251,000$1.49M
Total assets$6.96M$7.93M$9.20M$12.74M$18.07M
Current liabilities$5.00M$6.11M$6.12M$13.31M$14.46M
Short-term debt$1.26M$677,000——$310,000
Long-term debt$387,000$0——$0
Total debt$1.65M$677,000——$310,000
Total liabilities$5.49M$6.13M$6.30M$13.51M$14.52M
Shareholders' equity$1.47M$1.79M$2.90M-$777,000$3.54M
Net debt$1.37M$223,000——-$1.06M
Shares outstanding184.26M184.26M161.68M152.10M112.48M
Cash flow statement
Operating cash flow-$407,000-$861,000$2.25M-$1.89M-$7.49M
Capital expenditure$109,000$18,000$0$0$35,000
Free cash flow-$516,000-$879,000$2.25M-$1.89M-$7.52M
Investing cash flow-$109,000-$28,000-$156,000$0-$35,000
Financing cash flow$337,000$32,000-$1.39M$1.12M$4.37M
Depreciation & amortization$192,000$334,000$235,000$992,000$1.15M
Stock-based compensation$497,000$258,000$218,000$1.01M$3.21M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.